title: Spores from two distinct colony types of the strain Bacillus subtilis PB6 substantiate anti-inflammatory probiotic effects in mice.
abstract: OBJECTIVE
  Reducing symptoms of inflammatory bowel diseases (IBD) by dietary supplements represents more than ever an attractive clinical approach. Since the use of spore forming bacteria may offer interesting advantages, the aim of the study was to address the anti-inflammatory potential of Bacillus >subtilis strain PB6 (ATCC - PTA 6737) spores, provided as a powder preparation.
  
  
  METHODS
  The immunomodulatory potential of strain PB6 was first characterized in vitro on human immunocompetent cells for both the commercial spore powder (Anaban™) and two phenotypic variants of the vegetative form. Assessment of the in vivo anti-inflammatory capacity of the standard spore powder and a variant spore powder preparation was performed using a mouse model of acute, TNBS-induced colitis. Performance was compared with the drug prednisolone, and was based on blinded macroscopic and histological scores, blood inflammatory markers and measurements of infiltration of mucosal neutrophils.
  
  
  RESULTS
  Strain PB6 induced substantial levels of IL-10 but very low levels of IL-12, TNFα and IFNγ on human PBMC. Both spore powders prevented colitis as shown by significant reductions of near all inflammatory read-outs.
  
  
  CONCLUSIONS
  B. subtilis strain PB6, provided as a preparation of spores, shows pre-clinical anti-inflammatory effects, suggesting further evaluation in a clinical intervention trial, e.g. with IBD type patients.
authors: Institut Pasteur de Lille, Lactic Acid Bacteria & Mucosal Immunity, Center for Infection and Immunity of Lille, 1, rue du Pr Calmette, BP 245, F-59019 Lille, France.
authors: Benoît
authors: B
authors: Foligné
authors: Eric
authors: E
authors: Peys
authors: Jan
authors: J
authors: Vandenkerckhove
authors: Johan
authors: J
authors: Van Hemel
authors: Joëlle
authors: J
authors: Dewulf
authors: Jérôme
authors: J
authors: Breton
authors: Bruno
authors: B
authors: Pot
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D001412:Bacillus subtilis; D001835:Body Weight; D002460:Cell Line; D003092:Colitis / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control*; D004195:Disease Models, Animal; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000382:microbiology / Q000517:prevention & control; D007371:Interferon-gamma / Q000097:blood; D016753:Interleukin-10 / Q000097:blood; D018664:Interleukin-12 / Q000097:blood; D007963:Leukocytes, Mononuclear / Q000378:metabolism / Q000382:microbiology; D051379:Mice; D009504:Neutrophils / Q000473:pathology; D019936:Probiotics / Q000008:administration & dosage*; D000685:Serum Amyloid A Protein / Q000032:analysis; D013171:Spores, Bacterial; D014302:Trinitrobenzenesulfonic Acid / Q000009:adverse effects; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
chemical_list: D000893:Anti-Inflammatory Agents; D000685:Serum Amyloid A Protein; D014409:Tumor Necrosis Factor-alpha; D016753:Interleukin-10; D018664:Interleukin-12; D007371:Interferon-gamma; D014302:Trinitrobenzenesulfonic Acid